Incommensurate-Commensurate Magnetic Phase Transition in SmRu2_{2}Al10_{10}

Magnetic properties of single crystalline SmRu$_{2}$Al$_{10}$ have been investigated by electrical resistivity, magnetic susceptibility, and specific heat. We have confirmed the successive magnetic phase transitions at $T_{\text{N}}=12.3$ K and $T_{\text{M}}=5.6$ K. Resonant x-ray diffraction has also been performed to study the magnetic structures. Below $T_{\text{N}}$, the Sm$^{3+}$ moments order in an incommensurate structure with $q_1=(0, 0.759, 0)$. The magnetic moments are oriented along the orthorhombic $b$ axis, which coincides with the magnetization easy axis in the paramagnetic phase. A very weak third harmonic peak is also observed at $q_3=(0, 0.278, 0)$. The transition at $T_{\text{M}}$ is a lock-in transition to the commensurate structure described by $q_1=(0, 0.75, 0)$. A well developed third harmonic peak is observed at $q_3=(0, 0.25, 0)$. From the discussion of the magnetic structure, we propose that the long-range RKKY interaction plays an important role, in addition to the strong nearest neighbor antiferromagnetic interaction.Comment: 11 pages, 12 figures, accepted in PR

Stable Existence of Phase IV inside Phase II under Pressure in Ce0.8_{0.8}La0.2_{0.2}B6_{6}

We investigate the pressure effect of the electrical resistivity and magnetization of Ce$_{0.8}$La$_{0.2}$B$_{6}$. The situation in which phase IV stably exists inside phase II at H=0 T could be realized by applying a pressure above $P\sim 1.1$ GPa. This originates from the fact that the stability of phase II under pressure is larger than those of phases IV and III. The results seem to be difficult to reproduce by taking the four interactions of $\Gamma_{\mathrm{5u}}$-type AFO, $O_{xy}$-type AFQ, $T_{xyz}$-type AFO, and AF exchange into account within a mean-field calculation framework.Comment: 4 pages, 5 figures, to appear in J. Phys. Soc. Jpn. 79 (2010) No.

Kondo effect in CeXc_{c} (Xc_{c}=S, Se, Te) studied by electrical resistivity under high pressure

We have measured the electrical resistivity of cerium monochalcogenices, CeS, CeSe, and CeTe, under high pressures up to 8 GPa. Pressure dependences of the antiferromagnetic ordering temperature $T_{N}$, crystal field splitting, and the $\ln T$ anomaly of the Kondo effect have been studied to cover the whole region from the magnetic ordering regime at low pressure to the Fermi liquid regime at high pressure. $T_{N}$ initially increases with increasing pressure, and starts to decrease at high pressure as expected from the Doniach's diagram. Simultaneously, the $\ln T$ behavior in the resistivity is enhanced, indicating the enhancement of the Kondo effect by pressure. It is also characteristic in CeX$_{c}$ that the crystal field splitting rapidly decreases at a common rate of $-12.2$ K/GPa. This leads to the increase in the degeneracy of the $f$ state and further enhancement of the Kondo effect. It is shown that the pressure dependent degeneracy of the $f$ state is a key factor to understand the pressure dependence of $T_{N}$, Kondo effect, magnetoresistance, and the peak structure in the temperature dependence of resistivity.Comment: 9 pages, 5 figures, accepted for publication in J. Phys. Soc. Jp

X-Ray Diffraction Study of CeT2Al10 (T = Ru, Os) at Low Temperatures and under Pressures

We have carried out a powder X-ray diffraction investigation on antiferromagnetic Kondo semiconductorsCeRu2Al10 and CeOs2Al10 at low temperatures and under high pressures as well as the structural investigationon single crystal of these compounds. The results of powder X-ray studies of CeRu2Al10 and CeOs2Al10 indicatethat these compounds do not have structural transition at its antiferromagnetic ordering temperature. The resultsof single crystal structural refinement indicate that the b-axis of this crystal structure is insensitive not only topressure but also to temperature and that the effect of cooling to Ce–Ce distance for CeRu2Al10 is the same asthat for CeOs2Al10

Adenoviral p53 gene therapy for lung cancer

To determine the feasibility, safety, humoral immune response, and biological activity of multiple intratumoral injections of Ad5CMV-p53, and to characterize the pharmacokinetics of Ad5CMV-p53 in patients with advanced non-small cell lung cancer (NSCLC). Fifteen patients with histologically confirmed NSCLC and p53 mutations were enrolled into this phase I trial. Nine patients received escalating dose levels of Ad5CMV-p53 (1 × 109 to 1 × 1011 plaque-forming units[PFU]) as monotherapy once every 4 weeks. Six patients were treated on a 28-day schedule with Ad5CMV-p53 in combination with intravenous administration of cisplatin (80 mg/m2). Patients were monitored for toxicity, vector distribution, antibody formation, and tumor response. Fifteen patients received a total of 63 intratumoral injections of Ad5CMV-p53 without dose-limiting toxicity. The most common treatment-related toxicity was a transient fever. Specific p53 transgene expression was detected using reverse-transcriptase polymerase chain reaction in biopsied tumor tissues throughout the period of treatment despite of the presence of neutralizing anti-adenovirus antibody. Distribution studies revealed that the vector was detected in the gargle and plasma, but rarely in the urine. Thirteen of 15 patients were assessable for efficacy; one patient had a partial response (squamous cell carcinoma at the carina), 10 patients had stable disease, with three lasting ≥9 months, and 2 patients had progressive disease. Multiple courses of intratumoral Ad5CMV-p53 injection alone or in combination with intravenous administration of cisplatin were feasible and well tolerated in advanced NSCLC patients, and appeared to provide clinical benefit